Fonar Corporation and Dr. Raymond Damadian, Appellants/cross-Appellees v. Johnson & Johnson and Technicare Corporation, Appellees/cross-Appellants

821 F.2d 627, 3 U.S.P.Q. 2d (BNA) 1109, 1987 U.S. App. LEXIS 345
CourtCourt of Appeals for the Federal Circuit
DecidedJune 16, 1987
DocketAppeal 86-1005, 86-1019
StatusPublished
Cited by84 cases

This text of 821 F.2d 627 (Fonar Corporation and Dr. Raymond Damadian, Appellants/cross-Appellees v. Johnson & Johnson and Technicare Corporation, Appellees/cross-Appellants) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fonar Corporation and Dr. Raymond Damadian, Appellants/cross-Appellees v. Johnson & Johnson and Technicare Corporation, Appellees/cross-Appellants, 821 F.2d 627, 3 U.S.P.Q. 2d (BNA) 1109, 1987 U.S. App. LEXIS 345 (Fed. Cir. 1987).

Opinion

MARKEY, Chief Judge.

Appeal and cross-appeal from a judgment of the United States District Court *629 for the District of Massachusetts, 630 F.Supp. 581, 230 USPQ 105 (1986) (Keeton, J.). In Appeal No. 86-1005, Fonar Corporation and Dr. Raymond Damadian (collectively Fonar) (1) appeal from an order granting a judgment notwithstanding the verdict (JNOV) and holding that defendants Johnson & Johnson and its subsidiary Technicare Corporation (collectively J & J) have not infringed or induced infringement of claims 1 and 2 of U.S. Patent No. 3,789,-832, and (2) seek a new trial on the issues of infringement and validity of claims 7, 8 and 10 of that patent. We affirm the judgment that claims 1 and 2 are not infringed and deny Fonar’s request that this court order a new trial.

In Appeal No. 86-1019, J & J appeals from a judgment entered on a jury verdict that J & J failed to establish invalidity or unenforceability of claims 1 and 2 of U.S. Patent No. 3,789,832. We vacate the judgment appealed from and dismiss that appeal as moot.

BACKGROUND

I. The Invention

Fonar Corporation is the exclusive licensee of U.S. Patent No. 3,789,832 (’832 patent), entitled “Apparatus and Method for Detecting Cancer in Tissue,” issued February 5, 1974 to Raymond V. Damadian, on an application filed March 17, 1972. The ’832 patent discloses an apparatus and method employing nuclear magnetic resonance (NMR).

NMR techniques rely on the fact that the nuclei of some atoms, including hydrogen atoms, have a “spin”, which causes them to act like tiny bar magnets. When exposed to an external magnetic field, they align with it just as a compass needle aligns with the earth’s magnetic field. If aligned nuclei absorb applied electromagnetic energy of proper high frequency, however, they jump to a higher energy state and out of alignment with the external magnetic field. Under proper conditions, excited nuclei in a sample can generate a signal that can be detected. In a process called “relaxation,” when the applied high frequency is removed, the nuclei release their absorbed energy and realign with the external magnetic field, while the signal decays. Numbers called “spin-lattice relaxation time” (Ti) and “spin-spin relaxation time” (T2) communicate information about the physical state of the nuclei in a sample.

In 1970, Dr. Raymond Damadian conducted research to test his theory that hydrogen nuclei in water molecules in cancerous tissue would exhibit spin-lattice and spin-spin relaxation times different from those of water molecules in normal tissue. After obtaining encouraging results, Dr. Damadian applied for and obtained the ’832 patent.

Claims 1 and 2 of the ’832 patent read:

1. A method for detecting cancer comprising:

a. measuring and establishing standard NMR spin-lattice relaxation times and spin-spin relaxation times for both normal and cancerous tissue of the type under analysis using as an indicator nuclei at least one nuclei which exhibits deviant behavior in cancerous tissue;

b. measuring the NMR spin-lattice relaxation times and spin-spin relaxation times for the suspected tissue to determine the extent of deviant behavior of the indicator nuclei; and

c. comparing the values obtained in (b) against the standards obtained in (a).

2. The method of claim 1, wherein the indicator nuclei are cell water protons.

In the late 1970s, Dr. Damadian constructed an NMR apparatus large enough for a human being to be placed within it. Since then, a medical NMR industry (now called Magnetic Resonance Imaging, or MRI) has developed. Doctors use NMR machines to help them decide what is wrong with their patients and what to do about it.

NMR imaging machines display NMR response signal amplitude from points in the body to form an image on a screen. NMR signal amplitude depends on three factors, of which Ti and T2 make the greatest contribution, but NMR imaging does not *630 require numerical computation of Ti and T*.

II. Procedural History

J & J manufactures NMR imaging machines. On September 20, 1982, Fonar sued J & J, alleging that J & J had willfully infringed and induced infringement of the '832 patent, and that J & J had engaged in unfair competition. J & J answered that the ’832 patent was invalid and not infringed, and counterclaimed that the ’832 patent was invalid and unenforceable for failure to disclose “relevant material facts” to the Patent and Trademark Office.

At the beginning of trial, Fonar withdrew its unfair competition claim and limited the asserted patent claims to method claims 1, 2, 7, 8 and 10 of the '832 patent. J & J apparently limited its counterclaim, as well, to those claims. Trial was conducted, and the jury rendered its verdict, only on those claims.

The district court conducted a 23-day jury trial on the liability phase of the case in October and November 1985. The jury answered special verdict questions in accordance with Fed.R.Civ.P. 49(a), including eight questions on infringement. The jury found that J & J had infringed or induced infringement, both literally and under the doctrine of equivalents, of claims 1 and 2, but had not willfully done so. The jury found claims 7, 8 and 10 not infringed. As Judge Keeton’s opinion recounts, 630 F.Supp. at 581-82, 230 USPQ at 105-06, the jury found claims 1 and 2 valid and enforceable, and claims 7, 8 and 10 invalid.

J & J moved for JNOV, or in the alternative, for a new trial. The district court granted that portion of J & J’s JNOV motion requesting a holding of noninfringement of claims 1 and 2, but denied that portion requesting a holding that claims 1 and 2 were invalid and unenforceable. The court also denied J & J’s motion for a new trial.

III. The District Court’s Opinion

The “central dispute”, said Judge Keeton, was “whether reasonable persons could find that the evidence supports contentions of infringement of the method claims as permissibly interpreted.” 630 F.Supp. at 584, 230 USPQ at 107.

Fonar interpreted the phrase “measuring and establishing standard” Tj and T2 values in claim 1 and dependent claim 2 as meaning the experience and images carried in the minds of doctors. Judge Keeton, however, concluded that Fonar’s interpretation was “extraordinary” and “impermissible — a meaning that cannot be accepted by a reasonable person.” 630 F.Supp. at 586, 230 USPQ at 109. Judge Keeton said:

The argument becomes a distortion of common sense meaning when [Fonar] asserts] that a diagnostician is “measuring and establishing standard” NMR relaxation times when, with accumulated experience, the diagnostician learns to draw inferences from the shapes of images observed during extensive experience, stores in personal memory those images as standards, and then compares the standards with the images seen as the diagnostician examines suspected tissue for the purpose of detecting cancer.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

American Innotek, Inc. v. United States
126 Fed. Cl. 468 (Federal Claims, 2016)
Deston Therapeutics LLC v. Trigen Laboratories Inc.
723 F. Supp. 2d 665 (D. Delaware, 2010)
Garmin Ltd. v. TomTom, Inc.
468 F. Supp. 2d 988 (W.D. Wisconsin, 2006)
Arminak & Associates, Inc. v. Saint-Gobain Calmar, Inc.
424 F. Supp. 2d 1188 (C.D. California, 2006)
Ade Corp. v. KLA-Tencor Corp.
220 F. Supp. 2d 303 (D. Delaware, 2002)
TM Patents, LLP v. International Business MacHines Corp.
136 F. Supp. 2d 209 (S.D. New York, 2001)
Epcon Gas Systems, Inc. v. Bauer Compressors, Inc.
134 F. Supp. 2d 838 (E.D. Michigan, 2000)
Dentsply International, Inc. v. Great White, Inc.
132 F. Supp. 2d 310 (M.D. Pennsylvania, 2000)
Cargo Protectors, Inc. v. American Lock Co.
92 F. Supp. 2d 926 (D. Minnesota, 2000)
Medtronic, Inc. v. Advanced Cardiovascular Systems, Inc.
182 F. Supp. 2d 810 (D. Minnesota, 2000)
TM Patents, L.P v. International Business MacHines Corp.
72 F. Supp. 2d 370 (S.D. New York, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
821 F.2d 627, 3 U.S.P.Q. 2d (BNA) 1109, 1987 U.S. App. LEXIS 345, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fonar-corporation-and-dr-raymond-damadian-appellantscross-appellees-v-cafc-1987.